MRC1 and neoplasm: Compared to the control group (tumor cells co-injected with untreated macrophages), the treated group (tumor cells co-injected with macrophages pre-treated with SPIONs (+)) display an increase in CD80 (M1 marker) and a decrease in CD206 (M2 marker) in vivo.